Romania -
Romanian -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
teurlata 37,5 mg
pharmadox healthcare ltd. - malta - sunitinibum - caps. - 37,5mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
Romania -
Romanian -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
teurlata 50 mg
pharmadox healthcare ltd. - malta - sunitinibum - caps. - 50mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
Romania -
Romanian -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
klertis 25 mg
egis pharmaceuticals plc - ungaria - sunitinibum - caps. - 25mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
Romania -
Romanian -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
klertis 50 mg
egis pharmaceuticals plc - ungaria - sunitinibum - caps. - 50mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
European Union -
Romanian -
EMA (European Medicines Agency)
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agenți antineoplazici - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
Romania -
Romanian -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
klertis 12,5 mg
egis pharmaceuticals plc - ungaria - sunitinibum - caps. - 12,5mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
Romania -
Romanian -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
sutent 12,5 mg
pfizer italia srl - italia - sunitinibum - caps. - 12,5mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
Romania -
Romanian -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
sutent 25mg
pfizer italia srl - italia - sunitinibum - caps. - 25mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
Romania -
Romanian -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
sutent 50 mg
pfizer italia srl - italia - sunitinibum - caps. - 50mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
European Union -
Romanian -
EMA (European Medicines Agency)
inlyta
pfizer europe ma eeig - axitinib - carcinomul, celula renală - protein kinazei - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.